aTyr Pharma gets FDA orphan drug designation for efzofitimod in systemic sclerosis

aTYR PHARMA INC

FDA granted orphan drug designation for efzofitimod to treat systemic sclerosis (scleroderma) on April 12, 2022.
Efzofitimod is aTyr's lead therapeutic candidate; orphan status provides development incentives and market exclusivity potential.
Systemic sclerosis is a rare autoimmune disease; designation underscores unmet medical need.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.